Georgia Medicare Diabetes Screening: Section 1861(yy) Guide (2026)

title: Georgia Medicare Diabetes Screening Guide subtitle: A plain-English walkthrough of the Section 1861(yy) screening benefit for Georgia Medicare beneficiaries, primary care providers, and caregivers, including who qualifies, what tests are covered, how often, and what you pay.

For every Georgia Medicare beneficiary with diabetes risk factors asking whether their fasting glucose or HbA1c blood test is covered without out-of-pocket cost, every primary care provider conducting Annual Wellness Visits in Atlanta, Augusta, Savannah, Columbus, Macon, Albany, and rural Georgia communities, every diabetes educator coordinating prevention and management programs across Georgia health systems, every endocrinologist counseling Medicare patients about diabetes risk and prevention, and every Georgia caregiver supporting a family member through diabetes risk assessment, the Medicare diabetes screening benefit is a no-cost-sharing preventive screening codified at Section 1861(yy) of the Social Security Act.

Section 1861(yy) provides the statutory authority. National Coverage Determination 190.21 specifies acceptable screening tests (fasting plasma glucose, two-hour post-glucose-challenge glucose tolerance test, and HbA1c). Implementing regulations at 42 CFR 410.18 establish risk-factor-based eligibility and screening frequency. The ACA Section 4104 preventive services cost-sharing waiver eliminates beneficiary out-of-pocket cost. The diabetes screening benefit serves as the entry point to Medicare's broader diabetes prevention, education, and management framework.

By Brevy Care Team · Last verified May 21, 2026

The Federal Statutory Framework for Georgia Medicare Diabetes Screening

Section 1861(yy) of the Social Security Act

Section 1861(yy) of the Social Security Act (codified at 42 U.S.C. 1395x(yy)) defines the diabetes screening tests covered by Medicare. The statute authorizes Medicare to cover diabetes screening tests for the early detection of diabetes mellitus in beneficiaries at risk for diabetes. The statute delegates to CMS the authority to:

• Define the specific tests covered
• Establish risk factor eligibility criteria
• Establish screening frequency
• Establish conditions for coverage
• Update covered tests as evidence evolves

CMS exercises this delegated authority primarily through National Coverage Determination 190.21 Diabetes Screening Tests. Section 1861(yy) was added to the Social Security Act by Section 613 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA, Public Law 108-173).

Medicare Prescription Drug, Improvement, and Modernization Act (MMA)

The MMA (Public Law 108-173) added Section 1861(yy) to the Social Security Act through its Section 613, established Medicare coverage of diabetes screening tests, authorized CMS to specify covered tests and frequency, provided for risk-factor-based eligibility, and coordinated the new benefit with the broader Medicare preventive services framework. MMA is the same legislation that established Medicare Part D prescription drug coverage and the modern Medicare Advantage program.

National Coverage Determination NCD 190.21

CMS implemented Section 1861(yy) through National Coverage Determination NCD 190.21 Diabetes Screening Tests. NCD 190.21 specifies:

• Covered tests: fasting plasma glucose (FPG), two-hour post-glucose-challenge glucose tolerance test (GTT), and HbA1c
• Eligible beneficiaries: beneficiaries with diabetes risk factors as defined
• Frequency: covered more often for risk-factor beneficiaries than for those already diagnosed with prediabetes; verify the current frequency limits on the Medicare diabetes screening coverage page before ordering
• Specimen requirements: as clinically appropriate for the selected test
• Provider requirements: order from a treating physician or other qualified non-physician practitioner

NCD 190.21 has been periodically updated to reflect evolving clinical evidence, including the addition of HbA1c as an acceptable screening test in a later CMS update.

42 CFR 410.18 Implementing Regulations

Implementing regulations at 42 CFR 410.18 address diabetes screening tests including the specific covered tests, risk-factor-based eligibility, frequency limitations, conditions for coverage, and documentation requirements. The regulation aligns with NCD 190.21 and provides the regulatory foundation for Medicare Administrative Contractor claim adjudication.

ACA Section 4104 Preventive Services Cost-Sharing Waiver

Section 4104 of the Patient Protection and Affordable Care Act (ACA, Public Law 111-148) eliminated Medicare beneficiary cost-sharing for certain preventive services. The cost-sharing waiver applies to preventive services rated A or B by the United States Preventive Services Task Force and to specific Medicare-defined preventive services including diabetes screening tests. Section 4104 waived the Part B deductible for covered preventive services and waived the standard 20 percent coinsurance.

The result is that Medicare beneficiaries pay nothing out-of-pocket for diabetes screening tests covered under Section 1861(yy) when furnished by a Medicare-enrolled provider accepting Medicare assignment.

Risk Factor-Based Eligibility

Diabetes Risk Factors

Under NCD 190.21, beneficiaries are eligible for diabetes screening if they have one or more of the following diabetes risk factors:

Cardiometabolic risk factors

• Hypertension
• Dyslipidemia
• Obesity

Diabetes-related history

• History of gestational diabetes mellitus
• History of delivering a high-birth-weight baby

Demographic risk factors

• Age 65 or older
• Family history of diabetes (parent, sibling, or child)
• Membership in a high-risk racial or ethnic group (African American, Hispanic/Latino, Asian American, American Indian/Alaska Native, Pacific Islander)

NCD 190.21 also identifies an automatic-eligibility pathway when a beneficiary carries two or more co-occurring risk factors from the cardiometabolic and history categories. Verify the current automatic-eligibility list on the CMS coverage page before relying on it for borderline cases.

Practical Eligibility

In practice, most Medicare beneficiaries (who are age 65 or older) meet the age-based eligibility criterion. Combined with the high prevalence of hypertension, dyslipidemia, and obesity in the Medicare population, the vast majority of Medicare beneficiaries qualify for the diabetes screening benefit. The risk-factor criteria function more to exclude very low-risk beneficiaries than to substantially narrow eligibility.

Documentation of Eligibility

The ordering provider documents the qualifying risk factor(s) in the medical record. Common documentation patterns include:

• "Age 65+, hypertension, dyslipidemia, eligible for diabetes screening"
• "Family history of diabetes plus obesity, diabetes screening ordered"
• "Prior gestational diabetes, annual diabetes screening"

Risk-factor documentation supports correct claim adjudication under the screening benefit.

Three Acceptable Screening Tests Under Section 1861(yy)

Fasting Plasma Glucose (FPG)

Fasting plasma glucose (FPG) measures blood glucose after an overnight fast (typically eight hours minimum). FPG is the simplest, most widely available diabetes screening test:

• Specimen: venous blood after overnight fast
• Advantages: widely available, low cost, well-understood
• Limitations: requires fasting; subject to acute glucose variability

Two-Hour Post-Glucose-Challenge Glucose Tolerance Test (GTT)

The oral glucose tolerance test (OGTT) measures blood glucose at baseline and two hours after a standardized oral glucose challenge:

• Specimen: multiple venous blood draws (baseline and post-challenge)
• Advantages: more sensitive for early glucose dysregulation than FPG
• Limitations: time-consuming (multi-hour visit), patient burden, less commonly used in screening

The GTT is more commonly used in pregnancy-related gestational diabetes screening; in non-pregnancy adult diabetes screening, FPG and HbA1c are more commonly used.

HbA1c (Glycated Hemoglobin)

HbA1c measures average blood glucose over the prior two to three months by quantifying the percentage of hemoglobin with glucose attached. HbA1c is widely used for diabetes screening:

• Specimen: venous blood (no fasting required)
• Advantages: no fasting required, reflects longer-term glucose control, convenient
• Limitations: affected by certain hemoglobin variants, some racial differences in HbA1c-to-glucose correlation, not used in pregnancy

CMS added HbA1c as an acceptable diabetes screening test in a later NCD update reflecting clinical practice evolution; check the current NCD 190.21 page for the most recent version.

Provider Selection

The ordering provider selects the most clinically appropriate test for the individual beneficiary based on:

• Patient preference and adherence (HbA1c if fasting is difficult)
• Clinical context (FPG or GTT in pregnancy-related screening)
• Laboratory availability
• Prior testing history
• Comorbidities affecting test interpretation

Most ambulatory primary care diabetes screening for older adults uses HbA1c or FPG given convenience and clinical utility.

Screening Frequency

Risk-Factor Beneficiaries

Medicare covers diabetes screening more frequently for beneficiaries with risk factors who have not been diagnosed with prediabetes or diabetes. Beneficiaries with previously diagnosed prediabetes are eligible for a reduced screening frequency aligned with prediabetes monitoring guidance. Verify the current covered frequency on the Medicare diabetes screening coverage page before ordering, since the frequency parameters can be updated by CMS through NCD revisions.

Once Diagnosed With Diabetes

Once a beneficiary is diagnosed with diabetes, ongoing glucose monitoring (HbA1c, glucose measurements) is performed under diagnostic testing rules rather than under the screening benefit. Diagnostic testing follows standard Part B cost-sharing (deductible plus 20 percent coinsurance).

Frequency Tracking

Providers and beneficiaries should track:

• Last diabetes screening test date
• Whether the prior test was screening (Section 1861(yy)) or diagnostic
• Risk-factor status updates
• Prediabetes versus diabetes diagnosis status

EMR-based tracking supports systematic adherence to screening frequency rules.

Distinction Between Screening and Diagnostic Testing

Screening Diabetes Tests (No Cost-Sharing)

The Section 1861(yy) diabetes screening benefit applies when:

• The beneficiary has documented diabetes risk factors
• The beneficiary has not been diagnosed with diabetes
• The test is ordered as preventive screening
• The order falls within the covered screening frequency
• The provider codes the encounter with the appropriate screening ICD-10 code (typically Z13.1)

Under these conditions, Medicare pays 100 percent of the Medicare-approved amount; the beneficiary pays nothing.

Diagnostic Glucose Testing (Standard Cost-Sharing)

When glucose or HbA1c testing is ordered for diagnostic, monitoring, or treatment-management purposes, including:

• Established diabetes monitoring
• Evaluation of symptomatic hyperglycemia
• Workup of metabolic syndrome
• Pregnancy-related glucose evaluation in non-screening contexts
• Treatment response monitoring

The standard Part B coverage applies: the Part B deductible applies, and after the deductible, the beneficiary pays 20 percent coinsurance.

Practical Implications

In practice, primary care providers managing Medicare beneficiaries combine the diabetes screening test (when due under frequency rules) with broader preventive services during the AWV. For beneficiaries with established diabetes, glucose and HbA1c testing typically occur more frequently than the screening cadence, under diagnostic coverage with cost-sharing.

Coordination With the Initial Preventive Physical Examination

Section 1861(ww) IPPE

The Initial Preventive Physical Examination (IPPE), also called the "Welcome to Medicare Visit," is codified at Section 1861(ww) of the Social Security Act. The IPPE provides a one-time preventive physical examination available within the first 12 months of Medicare Part B enrollment. The IPPE includes:

• Review of medical and social history with focus on health risk factors
• Measurement of vital signs including blood pressure and BMI
• Cardiovascular risk assessment
• Diabetes risk-factor assessment
• Health education and counseling
• Referrals for needed preventive services

The IPPE is the natural entry point for ordering the Medicare diabetes screening test for newly Medicare-enrolled beneficiaries.

IPPE Diabetes Risk Assessment

During the IPPE, the provider assesses diabetes risk factors including personal history of risk conditions (hypertension, dyslipidemia, obesity), family history of diabetes, age-based risk (Medicare-aged beneficiaries qualify by age alone), demographic risk, prior gestational diabetes history (for women), and lifestyle factors. Based on this assessment, the provider may order the diabetes screening test as part of the IPPE-initiated preventive plan.

IPPE Cost-Sharing

The IPPE itself is covered at no beneficiary cost-sharing under ACA Section 4104. When the diabetes screening test is ordered during or following the IPPE, the screening test is also covered at no cost-sharing. The IPPE therefore provides a single no-cost preventive encounter encompassing comprehensive baseline assessment and diabetes screening.

Coordination With the Annual Wellness Visit

Section 1861(hhh) AWV

The Annual Wellness Visit (AWV) is codified at Section 1861(hhh) of the Social Security Act. The AWV provides an annual preventive visit available after the IPPE (or after 12 months of Part B enrollment). The AWV includes:

• Establishment or update of personalized prevention plan services
• Health Risk Assessment (HRA)
• Review of medical and family history
• List of current providers and prescriptions
• Vital signs measurement
• Cognitive function screening
• Depression screening
• Functional ability and safety screening
• Personalized health advice and referrals
• Screening schedule

AWV Diabetes Screening Coordination

The AWV personalized prevention plan typically incorporates diabetes screening when due. During each AWV, the provider:

• Reviews the date of the last covered diabetes screening
• Determines whether screening is due
• Orders the appropriate test (typically HbA1c or FPG)
• Counsels on diabetes risk factors
• Coordinates with broader preventive services (cardiovascular screening, colorectal cancer screening, immunizations)
• Considers MDPP referral if prediabetes is identified

The AWV thus serves as the recurring annual touchpoint for diabetes screening management throughout a beneficiary's Medicare tenure.

AWV and Screening Cost-Sharing

The AWV is covered at no beneficiary cost-sharing under ACA Section 4104. When the diabetes screening test is ordered during the AWV, the screening test is also covered at no cost-sharing. The AWV-plus-screening encounter therefore provides cost-free preventive care.

Coordination With Medicare Diabetes Prevention Program

Section 1861(jjj) MDPP

The Medicare Diabetes Prevention Program (MDPP), codified at Section 1861(jjj) of the Social Security Act, is a structured intervention for prediabetes beneficiaries designed to prevent progression to type 2 diabetes. MDPP includes core sessions in the first half of the program year, maintenance sessions in the second half, ongoing maintenance sessions for beneficiaries meeting weight-loss goals, a CDC-recognized curriculum, trained lifestyle coaches, and a group-based behavioral intervention.

MDPP Eligibility

To qualify for MDPP, beneficiaries must meet:

• Medicare Part B coverage
• A BMI threshold meeting current CMS eligibility criteria
• A prediabetes-range result on a recent qualifying laboratory test (HbA1c, fasting plasma glucose, or two-hour OGTT)
• No previous diagnosis of type 1 or type 2 diabetes (other than gestational)
• No end-stage renal disease (ESRD) diagnosis

The diabetes screening test result is the gateway laboratory criterion for MDPP eligibility. A beneficiary identified with prediabetes through Section 1861(yy) screening may be referred to MDPP for the structured prevention intervention. Verify the current BMI and laboratory thresholds on the CMS MDPP page before counseling a borderline patient.

MDPP Cost-Sharing

Like the diabetes screening test, MDPP services are covered at zero beneficiary cost-sharing. The screening-plus-MDPP pathway provides comprehensive no-cost diabetes prevention for eligible Georgia Medicare beneficiaries.

Georgia MDPP Suppliers

MDPP services are furnished by CMS-enrolled MDPP suppliers. Georgia MDPP suppliers include hospital-based diabetes education programs, community health organizations, FQHCs, and other CDC-recognized DPP providers that have additionally enrolled with Medicare as MDPP suppliers.

Coordination With DSMT and MNT

Diabetes Self-Management Training (Section 1861(qq))

Following a diabetes diagnosis, beneficiaries access Diabetes Self-Management Training (DSMT) under Section 1861(qq):

• Initial training: training available in the period after diagnosis
• Subsequent years: annual follow-up training available
• Accreditation requirements: ADA Education Recognition Program, ADCES DEAP, or IHS DPAP
• Codes: HCPCS codes for individual and group DSMT sessions
• Cost-sharing: standard Part B deductible and 20 percent coinsurance apply (DSMT is not a preventive cost-sharing-waived service)

Verify the current covered hour totals on the Medicare DSMT coverage page.

Medical Nutrition Therapy (Section 1861(vv))

Following a diabetes diagnosis, beneficiaries also access Medical Nutrition Therapy (MNT) under Section 1861(vv):

• Initial year: MNT services in the first benefit year
• Subsequent years: annual MNT services
• Additional hours: available through a physician second referral for change in condition
• Codes: CPT codes for individual initial assessment, individual reassessment, and group sessions
• Cost-sharing: standard Part B deductible and 20 percent coinsurance apply

Verify the current covered hour totals on the Medicare MNT coverage page.

Sequential Care Pathway

The Medicare diabetes care framework provides a sequential pathway:

1. Screening (Section 1861(yy)), risk-factor-based screening identifies prediabetes or undiagnosed diabetes
2. Prevention (Section 1861(jjj) MDPP), prediabetes beneficiaries access structured prevention
3. Diagnosis, if diabetes develops, beneficiaries enter the diagnosed-diabetes care pathway
4. Education (Section 1861(qq) DSMT), diagnosed beneficiaries access diabetes education
5. Nutrition Therapy (Section 1861(vv) MNT), diagnosed beneficiaries access nutrition counseling
6. Ongoing Management, diagnostic testing, medication management, and complications screening

The diabetes screening benefit is the gateway to this comprehensive framework.

Service Codes for Georgia Medicare Diabetes Screening

Covered laboratory codes for diabetes screening include CPT codes for fasting plasma glucose, glucose tolerance testing with multiple specimens, and hemoglobin A1c. The specific CPT code used depends on the test ordered and the laboratory protocol. Confirm the current covered CPT codes against the Medicare Clinical Laboratory Fee Schedule and the Palmetto GBA (Georgia MAC) local coverage articles before billing.

Most ambulatory primary care diabetes screening for Medicare beneficiaries uses HbA1c (convenient, no fasting needed) or fasting plasma glucose (when fasting can be coordinated). Glucose tolerance testing is less commonly used in routine screening due to the time burden but may be used in specific clinical contexts.

Documentation Requirements

Ordering Provider Documentation

The ordering provider must document:

• Diabetes risk factor(s) qualifying the beneficiary for screening
• Indication for screening (diabetes screening)
• Date of the last covered screening (to verify frequency compliance)
• Appropriate ICD-10 coding (typically Z13.1 Encounter for screening for diabetes mellitus)
• A standing or specific order for the screening test

Laboratory Documentation

The performing laboratory documents:

• Specimen collection date and time
• Fasting status (if applicable to test interpretation)
• Test results with reference ranges
• Quality-control compliance
• Ordering provider identification

Claim Documentation

The Medicare claim must:

• Use the appropriate CPT code
• Use the appropriate ICD-10 screening diagnosis code (Z13.1 or similar)
• Identify the ordering provider
• Reflect assignment-accepting payment terms

Accurate documentation supports correct claim adjudication as screening (zero cost-sharing) versus diagnostic (cost-sharing applies).

Worked Examples

Example 1: Risk-Factor Screening 66-Year-Old in Cobb County

Mr. Patel, a 66-year-old Cobb County resident with hypertension, dyslipidemia, and obesity, visits his primary care provider at a Wellstar clinic for his Annual Wellness Visit. The provider notes Mr. Patel has multiple diabetes risk factors and has not had a diabetes screening test in the past year.

Order: The provider orders an HbA1c with ICD-10 Z13.1 (Encounter for screening for diabetes mellitus) at on-site phlebotomy. Specimen is processed; results return in the prediabetes range.

Coverage: The HbA1c test is covered under Section 1861(yy) at zero beneficiary cost-sharing because Mr. Patel has multiple qualifying risk factors, the screening is within the covered frequency, and the order is coded as screening.

Follow-up: The provider discusses the prediabetes result with Mr. Patel and refers him to MDPP (a CDC-recognized Wellstar diabetes prevention program) for the structured intervention. Mr. Patel will move to the prediabetes-diagnosed screening frequency going forward.

Example 2: Prediabetes-Diagnosed Annual Follow-Up Screening

Mrs. Sullivan, a 71-year-old Augusta resident, was previously diagnosed with prediabetes and completed an Augusta University Diabetes Center MDPP program. At her Annual Wellness Visit, the provider orders her follow-up HbA1c screening.

Order: HbA1c with ICD-10 Z13.1 plus R73.03 (prediabetes diagnosis history). The order documents the screening frequency applicable to prediabetes-diagnosed beneficiaries.

Coverage: The HbA1c is covered under Section 1861(yy) at zero cost-sharing. Mrs. Sullivan's result returns in the normal range, reflecting successful MDPP intervention. The provider discusses the encouraging result and emphasizes continued lifestyle maintenance.

Example 3: HbA1c Versus Fasting Plasma Glucose Selection

Ms. Davis, a 69-year-old Savannah resident with family history of diabetes plus obesity, requires diabetes screening at her AWV. The provider discusses test options:

• HbA1c: no fasting required, can be drawn at the AWV visit
• FPG: requires fasting, would require a return visit for an early-morning fasting draw

Ms. Davis prefers convenience and chooses HbA1c. The provider orders the HbA1c with ICD-10 Z13.1. Specimen drawn at visit; results return in the normal range.

Coverage: HbA1c covered at zero cost-sharing under Section 1861(yy). The convenience of HbA1c facilitates same-visit screening rather than requiring a separate fasting blood draw appointment.

Example 4: Diagnostic Versus Screening Pathway

Mr. Foster, a 68-year-old with established diabetes diagnosed several years ago, presents for diabetes follow-up. The provider orders HbA1c monitoring as part of routine diabetes management.

Coverage Pathway: Because Mr. Foster has established diabetes, the HbA1c is ordered as diagnostic testing for diabetes monitoring rather than as preventive screening. The order uses ICD-10 E11.9 (Type 2 diabetes mellitus without complications) rather than a screening Z code.

Cost-Sharing: The diagnostic HbA1c is covered under standard Part B rules. Mr. Foster pays the Part B deductible if not already met, and after the deductible, 20 percent coinsurance of the Medicare-approved amount. His Medicare Supplement plan may cover the coinsurance.

Implication: The diabetes screening benefit applies only to beneficiaries without a diabetes diagnosis. Established diabetes beneficiaries access ongoing glucose monitoring under diagnostic coverage with standard cost-sharing.

Example 5: Prediabetes to MDPP Enrollment Pathway

Mrs. Robinson, a 67-year-old Macon resident with overweight BMI and family history of diabetes, was screened with HbA1c at her AWV with a result in the prediabetes range. The provider:

1. Discusses the prediabetes result and progression risk
2. Reviews MDPP eligibility against the current CMS criteria, Mrs. Robinson meets them
3. Refers her to a CDC-recognized MDPP-enrolled program
4. Explains that MDPP is covered at zero cost-sharing
5. Schedules a follow-up to review progress

Coverage Bundle:

• AWV: zero cost-sharing
• HbA1c screening: zero cost-sharing (Section 1861(yy))
• MDPP: zero cost-sharing (Section 1861(jjj))
• Future follow-up HbA1c: zero cost-sharing (prediabetes follow-up frequency)

This integrated screening-and-prevention pathway is Medicare's frontline diabetes prevention strategy for at-risk beneficiaries.

Example 6: Rural Southwest Georgia FQHC Screening

Mr. Williams, a 73-year-old resident of Sylvester in Worth County, receives care at a Federally Qualified Health Center (FQHC). The FQHC primary care provider conducts his Annual Wellness Visit and notes elevated diabetes risk given his geographic location, hypertension (on antihypertensive medication), obesity, and a family history of type 2 diabetes.

Screening Order: The FQHC provider orders HbA1c with ICD-10 Z13.1 at the FQHC on-site phlebotomy. Specimen is sent to a regional laboratory for processing.

Coverage: The HbA1c is covered at zero beneficiary cost-sharing under Section 1861(yy) and ACA Section 4104. The FQHC primary care setting fully qualifies for the screening benefit.

Result and Follow-up: HbA1c returns in the prediabetes range. The provider refers Mr. Williams to a regional MDPP program (a Phoebe-affiliated program serving southwest Georgia). The screening-to-MDPP pathway provides critical diabetes prevention access in southwest Georgia communities with elevated cardiometabolic risk.

Georgia Diabetes Disease Burden

Prevalence

Georgia has a significant adult diabetes burden, with a large share of the adult population living with diagnosed diabetes and a meaningful additional share living with prediabetes. The Medicare-aged population (65+) has even higher diabetes prevalence reflecting age-related risk progression. Consult the Georgia Department of Public Health and CDC Behavioral Risk Factor Surveillance System (BRFSS) state pages for current Georgia-specific diabetes prevalence figures.

Geographic Distribution

Within Georgia, diabetes prevalence is geographically concentrated in:

• Rural southern Georgia counties
• Southwest Georgia (Albany, Bainbridge, Thomasville, Valdosta region)
• Coastal Georgia (Savannah, Brunswick region)
• Central Georgia (Macon, Augusta region in part)
• Rural eastern Georgia
• Atlanta inner-city neighborhoods with health disparities

The geographic distribution mirrors the broader cardiometabolic risk distribution and overlaps substantially with the Stroke Belt cardiovascular disease distribution.

Risk-Factor Burden

Georgia adults have elevated prevalence of obesity, hypertension, dyslipidemia, family history of diabetes (particularly in some communities), and cardiovascular disease. These overlapping risk factors elevate diabetes-screening eligibility and emphasize the importance of systematic screening in the Georgia Medicare population.

Diabetes Complications

Diabetes-related complications affecting the Georgia Medicare population include cardiovascular disease (heart attack, stroke), diabetic nephropathy (a leading cause of end-stage renal disease), diabetic retinopathy (a leading cause of working-age blindness), diabetic neuropathy, diabetic foot ulcers and lower-extremity amputation, and cognitive decline and dementia. Systematic diabetes screening enables early detection and intervention to delay or prevent these complications.

Major Georgia Diabetes Centers

Emory Diabetes Center

Emory Diabetes Center (Atlanta) is an academic diabetes care center with comprehensive services including endocrinology consultations, diabetes education (DSMT, ADA-recognized), medical nutrition therapy, insulin pump and continuous glucose monitoring management, diabetes complications screening (retinopathy, nephropathy, neuropathy), and diabetes research.

Wellstar Diabetes Education

Wellstar Diabetes Education provides ADA-recognized diabetes education across the Wellstar Health System's metropolitan Atlanta and north Georgia hospitals. Wellstar offers DSMT, MNT, MDPP-recognized prediabetes programs, and comprehensive diabetes care coordination.

Piedmont Diabetes Resource Center

Piedmont Atlanta Diabetes Resource Center provides comprehensive diabetes services within the Piedmont Healthcare system. Services include diabetes education, MNT, complications screening, and coordination with primary care.

Northside Hospital Diabetes Education

Northside Hospital Diabetes Education provides ADA-recognized DSMT programs at Northside's metropolitan Atlanta locations. Northside offers individual and group diabetes education.

Augusta University Diabetes Center

Augusta University Diabetes Center provides academic diabetes care for east Georgia. The center offers endocrinology consultations, DSMT, MNT, complications screening, and research opportunities.

Grady Diabetes Clinic

Grady Diabetes Clinic (Atlanta) provides comprehensive diabetes care for Atlanta's safety-net population. The clinic addresses the high diabetes burden in lower-income Atlanta neighborhoods.

Phoebe Diabetes Care Center

Phoebe Diabetes Care Center (Albany) provides diabetes care for southwest Georgia. The center addresses the elevated diabetes burden in southwest Georgia communities.

Other Georgia Diabetes Resources

Additional Georgia diabetes resources include:

• Memorial Health Diabetes Center (Savannah)
• St. Joseph's/Candler Diabetes Center (Savannah)
• Houston Healthcare Diabetes Education (Warner Robins)
• Floyd Healthcare Diabetes Education (Rome)
• University Hospital Diabetes Education (Augusta region)
• Hamilton Health Diabetes Education (Dalton)
• HRSA-supported FQHCs with diabetes services

Provider Settings for Diabetes Screening

Primary Care Provider Offices

Most Medicare diabetes screening orders originate from primary care provider offices, including internal medicine, family medicine, geriatrics, and endocrinology practices. Primary care providers conduct AWVs incorporating diabetes screening, order screening tests at on-site phlebotomy or through laboratory referral, counsel on diabetes risk and prevention, refer to MDPP, DSMT, or MNT as appropriate, and coordinate broader preventive care.

Federally Qualified Health Centers and Rural Health Clinics

FQHCs and RHCs throughout Georgia provide primary care including diabetes screening for Medicare beneficiaries. These settings serve underserved communities including many rural and southwest Georgia counties with elevated diabetes burden. FQHC and RHC services include AWV, diabetes screening, and care coordination.

Hospital Outpatient Clinics

Hospital outpatient primary care clinics affiliated with major Georgia health systems also provide diabetes screening for Medicare beneficiaries who receive primary care in these settings.

Independent Laboratory Patient Service Centers

Specimen collection occurs at provider-office on-site phlebotomy, Quest Diagnostics patient service centers, Labcorp patient service centers, hospital outpatient laboratories, and FQHC/RHC on-site phlebotomy.

Provider Best Practices

1. Systematic AWV implementation: use AWVs as the recurring touchpoint for diabetes screening management
2. Frequency tracking: EMR-based tracking of the last screening date and the next eligible date
3. Risk-factor documentation: document qualifying risk factors clearly to support claim adjudication
4. HbA1c preference for convenience: use HbA1c for beneficiaries where fasting coordination is difficult
5. Coordination with cardiovascular screening: pair diabetes screening with cardiovascular screening for an efficient single-visit comprehensive assessment
6. Coding accuracy: use appropriate screening Z codes (Z13.1) to ensure correct claim adjudication
7. MDPP referral pathway: implement a systematic workflow to refer prediabetes-identified beneficiaries to MDPP
8. Result-based intervention: coordinate prevention or treatment based on screening results
9. Care coordination: coordinate with endocrinology, diabetes education, and nutrition services
10. Lifestyle counseling: provide diet, physical activity, and weight management counseling
11. Family history documentation: capture family diabetes history for risk stratification
12. Beneficiary education: explain the zero-cost-sharing structure to remove perceived barriers
13. Follow-up tracking: ensure abnormal results lead to appropriate follow-up
14. EMR templates: use standardized screening order templates for consistency

Common Issues and Resolutions

1. Beneficiary charged cost-sharing for covered screening: occurs when the claim is coded with a diagnostic ICD-10 rather than a screening Z code. Resolution: provider claim correction with the appropriate Z code.
2. Screening ordered too frequently: a frequency violation results in claim denial. Resolution: verify the last screening date before ordering; if clinically necessary, order under diagnostic testing rules.
3. Established diabetes beneficiary misclassified for screening: established diabetes beneficiaries cannot receive the screening benefit. Resolution: order under diagnostic coverage with appropriate ICD-10 coding.
4. Provider unaware of zero cost-sharing: some providers incorrectly counsel beneficiaries about cost-sharing for screening. Resolution: provider education on the ACA Section 4104 cost-sharing waiver.
5. Beneficiary doesn't fast adequately for FPG: inadequate fasting affects FPG accuracy. Resolution: clear pre-test instructions or use HbA1c (no fasting required).
6. EMR doesn't flag screening eligibility: without EMR support, providers may miss screening opportunities. Resolution: implement EMR reminder systems for diabetes-screening eligibility.
7. Confusion with diagnostic glucose testing frequency: the screening frequency rules apply to screening only. Resolution: clarify diagnostic versus screening coding and pathway.
8. Missing AWV coordination: diabetes screening is most efficiently coordinated through AWV. Resolution: integrate screening into AWV workflows.
9. Specimen collection logistics: beneficiaries may not have transportation to specimen collection. Resolution: use on-site phlebotomy or mobile collection.
10. Provider missing MDPP referral opportunity: prediabetes results warrant MDPP referral. Resolution: implement a workflow to refer prediabetes beneficiaries to MDPP suppliers.
11. Beneficiary refuses screening due to perceived complexity: counseling about no cost-sharing and HbA1c convenience can address this. Resolution: clear beneficiary education.
12. HbA1c interpretation in specific populations: HbA1c can be affected by hemoglobin variants. Resolution: clinical judgment for test selection in affected populations.
13. Rural beneficiary access barriers: specimen collection access can be limited in rural areas. Resolution: use RHC, FQHC, mobile phlebotomy, or pharmacy-based collection.
14. Prediabetes follow-up frequency confusion: beneficiaries with diagnosed prediabetes follow a different screening cadence. Resolution: track prediabetes diagnosis status in the EMR.

A few more common questions:

When was the Medicare diabetes screening benefit established? The benefit was established by Section 613 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA, Public Law 108-173), which added Section 1861(yy) to the Social Security Act. CMS implemented the benefit through National Coverage Determination 190.21.

How often does Medicare cover diabetes screening? Frequency differs for risk-factor beneficiaries without a prediabetes or diabetes diagnosis versus beneficiaries previously diagnosed with prediabetes. Verify the current covered frequency on the Medicare diabetes screening coverage page before ordering.

Do I need to fast for the screening test? HbA1c does not require fasting and can be drawn at any time. Fasting plasma glucose requires an overnight (eight-hour) fast. The two-hour glucose tolerance test requires fasting plus a glucose drink and multiple blood draws over a multi-hour visit. Most beneficiaries use HbA1c for convenience.

Where can I get the screening test done? At primary care provider offices with on-site phlebotomy, hospital outpatient laboratories, Quest Diagnostics patient service centers, Labcorp patient service centers, FQHC and RHC on-site phlebotomy, and other Medicare-enrolled laboratory collection sites throughout Georgia.

What if I'm in Medicare Advantage (Part C)? Medicare Advantage plans must cover the same preventive services as Original Medicare at zero cost-sharing for in-network providers. Medicare Advantage beneficiaries access diabetes screening through their plan's network providers under the same Section 1861(yy) framework.

Can I have diabetes screening done at the same visit as cardiovascular screening? Yes. Diabetes screening (Section 1861(yy)) and cardiovascular disease screening (Section 1861(xx)) are commonly ordered together because both can be obtained from a single blood draw and both inform comprehensive cardiometabolic risk assessment. Both are covered at zero cost-sharing under ACA Section 4104.

Which ICD-10 code applies to diabetes screening? The typical screening ICD-10 code is Z13.1 (Encounter for screening for diabetes mellitus). The use of screening Z codes (rather than diagnostic ICD-10 codes) is what triggers Medicare claim processing under the screening benefit with zero cost-sharing.

Can rural Georgia beneficiaries access diabetes screening? Yes. Rural Georgia beneficiaries access screening through primary care providers, Federally Qualified Health Centers (FQHCs), Rural Health Clinics (RHCs), hospital outpatient clinics, and commercial laboratory patient service centers distributed throughout rural Georgia. The zero-cost-sharing structure removes financial barriers.